EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial

Bart Geboers, Florentine Timmer, Danielle Vos, Hester Scheffer, Joyce Bakker, Alette Ruarus, Laurien Vroomen, Anita Stam, Sinéad Lougheed, Evelien Schouten, Robbert Puijk, Petrousjka van den Tol und 5 weitere

Journal for ImmunoTherapy of Cancer · 2025-03 · 13 (3) · e010222

DOI: 10.1136/jitc-2024-010222 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 26.03.2025. Verfasst von Bart Geboers und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands bart.geboers@health.nsw.gov.au. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Radiosurgery, Electroporation, Immunomodulation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adessium Foundation, Cancer Center Amsterdam, Angiodynamics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Irreversible electroporation (IRE) and stereotactic ablative body radiotherapy (SABR) are cytoreductive therapies for locally advanced pancreatic cancer (LAPC). Both may signify immunogenic cell death. We aimed to compare systemic immune responses between the treatments.

Methods

As part of the randomized phase II CROSSFIRE trial ( NCT02791503 ), comparing the oncological efficacy of IRE to SABR in patients with LAPC, pre- and post-treatment (2 weeks and 3 months) peripheral blood samples were collected. Frequency and activation status of lymphocytic and myeloid subsets were determined using flow cytometry. T cell responses to pancreatic cancer associated with Wilms tumor-1 (WT-1) and survivin tumor antigens were determined by interferon-γ enzyme-linked immunospot assay.

Results

In total, 20 IRE and 20 SABR-treated participants were analyzed (20 men; median age 65 (IQR 55–70)). IRE induced immediate decreases in systemic regulatory T cell (Treg) and conventional type-1 dendritic cell rates, coinciding with CD4 + /CD8 + T cell activation by upregulation of PD-1, which was associated with improved overall survival (OS). SABR similarly induced immediate CD4 + /CD8 + T cell activation by upregulation of Ki67 and CD25 but resulted in asynchronously delayed Treg downregulation. SABR also induced a durable increase in CD4 + EM T cells, associated with improved OS. Ablation-induced WT-1 or survivin-specific T cell responses were observed in 9/16 (56%) immune competent participants (IRE n=5, SABR n=4) and were associated with longer OS.

Conclusion

Distinct immune stimulatory responses associated with improved OS, suggest that SABR might benefit from combined Treg depletion strategies while IRE could benefit from PD-1 checkpoint inhibition. Trial registration number The trial was registered on clinical trials.gov ( NCT02791503 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsRadiosurgeryElectroporationImmunomodulationHumansMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

AbscopalAdenocarcinomaImmune modulatory

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands bart.geboers@health.nsw.gov.au.
  • Cancer Centre Amsterdam, Amsterdam, The Netherlands.
  • Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Department of Medical Imaging, Prince of Wales Hospital, Sydney, New South Wales, Australia.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands.
  • Department of Radiology, Noord West Ziekenhuis Groep, Alkmaar, The Netherlands.

Förderung

  • Adessium Foundation
  • Cancer Center Amsterdam
  • Angiodynamics

Zitieren

APA

Geboers, B., Timmer, F., Vos, D., Scheffer, H., Bakker, J., Ruarus, A., Vroomen, L., Stam, A., Lougheed, S., Schouten, E., Puijk, R., van den Tol, P., Lagerwaard, F., de Vries, J., Bruynzeel, A., Meijerink, M., & de Gruijl, T. (2025). Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial. Journal for ImmunoTherapy of Cancer, 13(3), e010222. https://doi.org/10.1136/jitc-2024-010222

Vancouver

Geboers B, Timmer F, Vos D, Scheffer H, Bakker J, Ruarus A, et al. Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial. Journal for ImmunoTherapy of Cancer. 2025;13(3):e010222. doi:10.1136/jitc-2024-010222

BibTeX
@article{Geboers2025,
  author = {Geboers, Bart and Timmer, Florentine and Vos, Danielle and Scheffer, Hester and Bakker, Joyce and Ruarus, Alette and Vroomen, Laurien and Stam, Anita and Lougheed, Sinéad and Schouten, Evelien and Puijk, Robbert and van den Tol, Petrousjka and Lagerwaard, Frank and de Vries, Jan and Bruynzeel, Anna and Meijerink, Martijn and de Gruijl, Tanja},
  title = {Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {e010222},
  doi = {10.1136/jitc-2024-010222}
}
Kostenlos starten →